A new study published in The New England Journal of Medicine showed that daily dapagliflozin dramatically reduced the risk of ...

A randomized controlled trial investigated use of sodium glucose cotransporter 2 inhibitors (SGLT2i) on top of standard care immunosuppression in lupus nephritis.

Included in the open-label crossover SOGALDI-PEF study were adults with symptomatic heart failure (New York Heart Association ...

India accounts for 1 in 7 adults living with diabetes globally. An estimated 89.8 million adults aged 20-79 years in India ...

During follow-up, the primary outcome occurred in 16.4% of participants in the dapagliflozin group and 19.5% of participants in the placebo group, for an HR of 0.82 (95% CI, 0.73-0.92; P < .001).

The SGLT2 inhibitor dapagliflozin was associated with a reduced risk for hospitalization due to any cause in patients with chronic kidney disease with and without type 2 diabetes, according to a ...

"Dapagliflozin inhibits renal glucose reabsorption, promotes urinary excretion, and works independently of insulin action of secretion," Dr. Henry said during the presentation.

Dapagliflozin is a novel, selective, sodium glucose co-transporter 2 (SGLT2) inhibitor, currently being evaluated in Phase 3 trials as a once-daily oral therapy for the treatment of type 2 diabetes.

PHILADELPHIA, PA—Dapagliflozin added to optimal medical therapy results in meaningful improvements in symptoms and health-related quality of life in heart failure patients with reduced ejection ...

Whatever the mechanism of benefit from dapagliflozin (Farxiga) in patients with heart failure (HF), the drug — and potentially also other sodium-glucose cotransporter 2 (SGLT2) inhibitors ...

The researchers found that 53% of the 78 participants in the dapagliflozin group and 30% of the 76 participants in the placebo group had MASH improvement without worsening of fibrosis (risk ratio ...